Biological characteristics of the A1762T/G1764A mutant strain of hepatitis B virus in vivo

Leng,Xiao‑Hua; Chen,En‑Qiang; Du,Ling‑Yao; Bai,Lang; Gong,Dao‑Ying; Cheng,Xing; Huang,Fei‑Jun; Tang,Hong

doi:10.3892/mmr.2015.4072

Biological characteristics of the A1762T/G1764A mutant strain of hepatitis B virus in vivo

Authors:
- Xiao‑Hua Leng
- En‑Qiang Chen
- Ling‑Yao Du
- Lang Bai
- Dao‑Ying Gong
- Xing Cheng
- Fei‑Jun Huang
- Hong Tang
View Affiliations

Affiliations: Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Forensic Pathology, Medical School of Basic and Forensic Sciences, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: July 9, 2015 https://doi.org/10.3892/mmr.2015.4072
Pages: 5141-5148

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The double nucleotide, A1762T and G1764A exchange (TA mutation), in the hepatitis B virus (HBV) genome basal core promoter (BCP) region is a common viral mutation in patients with chronic HBV infection. This mutation is located in the binding site of hepatocyte nuclear factor 4 (HNF4), and a number of liver‑enriched transcription factors are involved in the regulation of HBV transcription and replication. The aim of the present study was to investigate the biological characteristics of the HBV strain with this mutation, and the effect of HNF4 inhibition on the replication of this strain in vivo. The results indicated that in vivo the HBV strain with the TA mutation supported a higher level of pregenomic RNA transcription and HBV DNA replication, compared with the wild‑type strain. Furthermore, the concentration of serum HBeAg in the TA mutant group was lower than that in the wild‑type strain. Following treatment of the mice with entecavir (ETV) or tenofovir disoproxil fumarate (TDF), the transcription and replication levels of wild‑type and mutant strains were reduced. In the groups treated with TDF, the inhibition effect was more marked. In hepatocytes in which HNF4 expression was specifically inhibited, the level of 3.5 kb mRNA of HBV was reduced compared with that in mouse cells with normal HNF4 expression, and HBV DNA replication levels were also reduced to a greater extent. Furthermore, following liver‑specific knockdown of HNF4, the reduction in variant virus expression was greater than that of the wild‑type virus. In conclusion, the replication capacity of HBV with the TA mutation was increased, and the mutation was associated with a reduction in serum HBeAg levels. This mutant strain remained sensitive to ETV and TDF, and HNF4 supported a higher replication level of TA mutant HBV in vivo

View Figures

View References

1	Dandri M, Lutgehetmann M and Petersen J: Experimental models and therapeutic approaches for HBV. Semin Immunopathol. 35:7–21. 2013. View Article : Google Scholar
2	Tacke F, Gehrke C, Luedde T, Heim A, Manns MP and Trautwein C: Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol. 78:8524–8535. 2004. View Article : Google Scholar : PubMed/NCBI
3	Gunther S, Piwon N and Will H: Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C (1653)→ T, A (1762)→ T and G (1764)→ A mutations in the core promoter. J Gen Virol. 79:375–380. 1998. View Article : Google Scholar
4	Laras A, Koskinas J and Hadziyannis SJ: In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. Virology. 295:86–96. 2002. View Article : Google Scholar : PubMed/NCBI
5	Li J, Buckwold VE, Hon MW and Ou JH: Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol. 73:1239–1244. 1999.PubMed/NCBI
6	Parekh S, Zoulim F, Ahn SH, et al: Genome replication, virion secretion and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol. 77:6601–6612. 2003. View Article : Google Scholar : PubMed/NCBI
7	Nelson PK, Mathers BM, Cowie B, et al: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 378:571–583. 2011. View Article : Google Scholar : PubMed/NCBI
8	Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepat. 11:97–107. 2004. View Article : Google Scholar : PubMed/NCBI
9	Maynard JE: Hepatitis B: Global importance and need for control. Vaccine. 8(Suppl): S18–S23. 1990. View Article : Google Scholar : PubMed/NCBI
10	Tseng TC, Liu CJ, Chen CL, et al: Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis. 205:54–63. 2012. View Article : Google Scholar
11	Chu CJ, Keeffe EB, Han SH, et al: Prevalence of HBV precore/core promoter variants in the United States. Hepatology. 38:619–628. 2003. View Article : Google Scholar : PubMed/NCBI
12	Ouneissa R, Bahri O, Alaya-Bouafif NB, et al: Frequency and clinical significance of core promoter and precore region mutations in Tunisian patients infected chronically with hepatitis B. J Med Virol. 84:1719–1726. 2012. View Article : Google Scholar : PubMed/NCBI
13	Will H, Reiser W, Weimer T, et al: Replication strategy of human hepatitis B virus. J Virol. 61:904–911. 1987.PubMed/NCBI
14	Sladek FM, Zhong WM, Lai E and Darnell JE Jr: Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev. 4:2353–2365. 1990. View Article : Google Scholar : PubMed/NCBI
15	Wang Z, Bishop EP and Burke PA: Expression profile analysis of the inflammatory response regulated by hepatocyte nuclear factor 4α. BMC genomics. 12:1282011. View Article : Google Scholar
16	Chen EQ, Sun H, Feng P, et al: Study of the expression levels of Hepatocyte nuclear factor 4 alpha and 3 beta in patients with different outcome of HBV infection. Virol J. 9:232012. View Article : Google Scholar : PubMed/NCBI
17	Xu L, Chen EQ, Lei J, et al: Pre-core/basal-core promoter and reverse transcriptase mutations in chronic HBV infected-patients. Hepatogastroenterology. 59:212–215. 2012.PubMed/NCBI
18	Buckwold VE, Xu Z, Chen M, Yen TS and Ou JH: Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol. 70:5845–5851. 1996.PubMed/NCBI
19	Liu FJ, Liu L, He F, et al: Establishment and primary application of a mouse model with hepatitis B virus replication. World J Gastroenterol. 13:5324–5330. 2007. View Article : Google Scholar : PubMed/NCBI
20	Tang H and McLachlan A: A pregenomic RNA sequence adjacent to DR1 and complementary to epsilon influences hepatitis B virus replication efficiency. Virology. 303:199–210. 2002. View Article : Google Scholar : PubMed/NCBI
21	Liu F, Song Y and Liu D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6:1258–1266. 1999. View Article : Google Scholar : PubMed/NCBI
22	Tang H, Delgermaa L, Huang F, et al: The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J Virol. 79:5548–5556. 2005. View Article : Google Scholar : PubMed/NCBI
23	Chen EQ, Gong DY, Leng XH, et al: Inhibiting the expression of hepatocyte nuclear factor 4 alpha attenuates lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice. Hepatobiliary Pancreat Dis Int. 11:624–629. 2012. View Article : Google Scholar : PubMed/NCBI
24	Ganem D and Prince AM: Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 350:1118–1129. 2004. View Article : Google Scholar : PubMed/NCBI
25	Sumi H, Yokosuka O, Seki N, et al: Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology. 37:19–26. 2003. View Article : Google Scholar
26	Pungpapong S, Kim WR and Poterucha JJ: Natural history of hepatitis B virus infection: An update for clinicians. Mayo Clin Proc. 82:967–975. 2007. View Article : Google Scholar : PubMed/NCBI
27	Tang H, Raney AK and McLachlan A: Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture. J Virol. 75:8937–8948. 2001. View Article : Google Scholar : PubMed/NCBI
28	Yu H, Zhu R, Zhu YZ, Chen Q and Zhu HG: Effects of mutations in the X gene of hepatitis B virus on the virus replication. Acta virologica. 56:101–110. 2012. View Article : Google Scholar : PubMed/NCBI
29	Kim do Y, Kim HJ, Lee CK, et al: Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. Liver Int. 27:47–53. 2007.PubMed/NCBI
30	Okamoto H, Tsuda F, Akahane Y, et al: Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol. 68:8102–8110. 1994.PubMed/NCBI
31	Scaglioni PP, Melegari M and Wands JR: Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology. 233:374–381. 1997. View Article : Google Scholar : PubMed/NCBI
32	Kim DW, Lee SA, Hwang ES, Kook YH and Kim BJ: Naturally occurring precore/core region mutations of hepatitis B virus genotype C related to hepatocellular carcinoma. PloS one. 7:e473722012. View Article : Google Scholar : PubMed/NCBI
33	Seeger C and Mason WS: Hepatitis B virus biology. Microbiol Mol Biol Rev. 64:51–68. 2000. View Article : Google Scholar : PubMed/NCBI
34	Dai J, Chen EQ, Bai L, et al: Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model. Virol J. 9:2802012. View Article : Google Scholar
35	Selabe SG, Song E, Burnett RJ and Mphahlele MJ: Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes. J Med Virol. 81:996–1001. 2009. View Article : Google Scholar : PubMed/NCBI
36	Koklu S, Tuna Y, Gulsen MT, et al: Long-term efficacy and safety of lamivudine, entecavir and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 11:88–94. 2013. View Article : Google Scholar
37	Su W and T H: Regulation of hepatitis B virus transcription and replication by liver-enriched transcriptional factors. World Chinese Journal of Digestology. 15:1237–1240. 2007.